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SUMMARY
We evaluated the association between urinary arsenic and the seroprevalence of total hepatitis A
antibodies (total anti-HAV: IgG and IgM) in 11 092 participants aged56 years using information
collected in the US National Health and Nutrition Examination Survey (2003–2012). Multivariate
logistic regression models evaluated associations between total anti-HAV and total urinary arsenic
defined as the sum of arsenite, arsenate, monomethylarsonate and dimethylarsinate (TUA1). Effect
modification by self-reported HAV immunization status was evaluated. Total anti-HAV
seroprevalence was 35·1% [95% confidence interval (CI) 33·3–36·9]. Seropositive status was associated
with higher arsenic levels and this association was modified by immunization status (P= 0·03). For
participants that received52 vaccine doses or did not know if they had received any doses, a positive
dose-response association was observed between increasing TUA1 and odds of total anti-HAV [odds
ratio (OR) 1·42, 95% CI 1·11–1·81; and OR 1·75, 95% CI 1·22–2·52], respectively. A positive but not
statistically significant association was observed in those who received <2 doses (OR 1·46, 95% CI
0·83–2·59) or no dose (OR 1·12, 95% CI 0·98–1·30). Our analysis indicates that prevalent arsenic
exposure was associated with positive total anti-HAV seroprevalence. Further studies are needed to
determine if arsenic increases the risk for incident hepatitis A infection or HAV seroconversion.
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NHANES.
INTRODUCTION
Hepatitis A virus (HAV) is transmitted via the faecal–
oral route and infection causes self-limiting liver dis-
ease which is generally asymptomatic or mild but
can presents with more severe symptoms including
fever, jaundice and occasionally fulminant hepatitis.
Globally, there are about 1·4 million cases of acute
hepatitis A per year with seroprevalence data suggest-
ing that HAV affects tens of millions of people annu-
ally. In parts of the world with poor sanitation
infrastructure, HAV infections tend to occur early in
life with an estimated 90% of children having an infec-
tion before the age of 10 years. However, in developed
countries with improved sanitation this pattern shifts
and HAV infections tend to occur later in life in ado-
lescents, adults and high-risk groups [1]. In the United
States, there were 1398 reported cases of acute HAV in
2011 with the actual number of cases estimated to be
between 1650 and 4370 [2]. Of these reported cases,
78% indicated they had not participated in any risk
behaviours for HAV transmission such as travel to
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an endemic area, men having sex with men (MSM),
injection drug use, or sex with multiple partners;
nor had they been exposed to any known infected
individuals [2].
In 1995, a vaccine against HAV became available in
the United States which markedly reduced HAV inci-
dence particularly after it was recommended as a rou-
tine vaccination for children in 1999. The vaccine was
introduced incrementally with a 1996 recommenda-
tion from the Advisory Committee on Immunization
Practices to vaccinate children living in communities
with the highest disease rates followed by states and
counties with elevated incidence rates [3]. Hepatitis
A vaccine in children is administered in a two-dose
series to children at age 12 months but it can also be
provided during subsequent visits if the child has not
been vaccinated at age 2 years. Adult immunization
is recommended for international travellers to coun-
tries where hepatitis A is endemic, MSM, illegal
drug users and other susceptible groups administered
as a three-dose series along with the hepatitis B
vaccine [4].
In 2009 hepatitis A immunization coverage estimates
in the United States for51 and52 vaccine doses ran-
ged from 29–58% and 6–24%, respectively [5].
Vaccination against HAV is very effective and studies
show that protective levels of anti-HAV antibodies de-
velop in 94–100% of adults 1 month after one dose of
the vaccine and 100% have protective HAV antibody
levels after two doses [6]. In children and adolescents,
97–100% have protective antibody levels 1 month
after the first dose and 100% reach protective levels 1
month after the second dose [6]. Additionally, a follow-
up study observed that after 5 years seroprotection
rates were 99·7% and 100% in 5-year-old children
who had received one and two doses, respectively [7].
Following inoculation, the immune system
responds by producing immunoglobulin G (IgG) anti-
bodies to the HAV. However, immunoglobulin M
(IgM) antibodies have been detected 2–3 weeks after
vaccination in 8–20% of adults. In the case of HAV in-
fection, IgM anti-HAV appear after 5–10 days before
the onset of symptoms but gradually disappear with
increasing IgG levels conferring long-term protection
against the virus. Subsequently, epidemiologists use
total anti-HAV (IgM and IgG) levels to estimate the
prevalence of previous hepatitis A infection [8]. Yet
despite the availability of an effective vaccine, hepa-
titis A remains a public health problem particularly
in highly endemic regions such as Central America,
South America, Africa, Middle East, South East
Asia and the South Pacific that have not fully imple-
mented vaccination programmes [9, 10].
Previous studies indicate that the severity and mor-
bidity of infectious diseases can be related to environ-
mental pollutants and exogenous chemical exposures
even at low levels [11]. The impact of environmental
contaminants on the immune system has been docu-
mented in several epidemiological studies in the past
decade. For example, an increased incidence of infec-
tions in children has been observed with elevated ex-
posure to dioxins, polychlorinated biphenyls and
polycyclic aromatic hydrocarbons [12, 13]. Emerging
evidence also suggests that arsenic is an immunotoxi-
cant [14]. Data from in vitro and in vivo studies show
that arsenic influences macrophage differentiation and
T-cell proliferation [15] and viral pathology [16].
Recent epidemiological studies report that elevated ar-
senic exposure during fetal development increases sus-
ceptibility to infectious diseases, including respiratory
diseases, diarrhoea and overall mortality in children
[17–20]. In addition, our group showed that urinary
arsenic levels were inversely associated with varicella
zoster virus IgG seroprevalence in the US population
aged 56 years [21]. Furthermore, a recent study in
pregnant women reported that urinary arsenic levels
was associated with increased odds of incident hepa-
titis E seroconversion suggesting that arsenic exposure
during pregnancy may enhance susceptibility to hepa-
titis E viral infection [22].
While the most effective way to reduce the global
burden of hepatitis A infection and transmission is
through active immunization and improved sanita-
tion, identifying environmental factors that can affect
infectious diseases could inform novel prevention
strategies to reduce the global burden of infectious dis-
eases. Subsequently, the objective of this study was to
investigate the cross-sectional association between ar-
senic exposure and immune response to HAV in a rep-
resentative sample of the US population. Given that
the National Health and Nutrition Examination
Survey (NHANES) only measured total anti-HAV
which cannot differentiate between antibodies pro-
duced by natural infection or vaccination, we limit
our hypothesis to determining if there was a significant
relationship between urinary arsenic levels and posi-
tive seroprevalence of total antibodies to HAV.
Furthermore, we hypothesized that hepatitis A im-
munization would modify this association after adjust-
ing for other risk factors because the production of
antibodies (IgG) produced by vaccination be lower
than levels produced after a natural infection.
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METHODS
Study population
We used data from the NHANES, a representative
cross-sectional survey designed to assess the health
and nutritional status of the US population, from
five consecutive cycles: 2003–2012. Response rates
for the five NHANES consecutive cycles were 76%,
77·36%, 75·4%, 77·3% and 69·5% [23]. Serological
markers for HAV were collected for participants aged
52 years while urinary arsenic measurements were col-
lected from participants aged56 years in all five survey
cycles. Total hepatitis A antibodies were tested for all
study participants while urinary arsenic was measured
in one-third of a subsample for each survey cycle.
Analytical methods for arsenic speciation and hepatitis
A serology were consistent across survey cycles.
Individuals were included in this analysis if they
were sampled for both urinary arsenic and total
hepatitis A serology. Participants with a positive or
equivocal HIV test were excluded from the analysis
to avoid confounding by immunodeficiency (n= 20).
Participants with an indeterminate serological test for
HAV were also excluded from the analysis (n= 1).
Analyses were further restricted by the availability of
covariates. Total urinary arsenic was determined
from urinary metabolites using two complementary
approaches. Total urinary arsenic 1 (TUA1) defined
as the sum of inorganic arsenic metabolites, and total
urinary arsenic 2 (TUA2) defined as total urinary ar-
senic minus non-toxic arsenosugar metabolites
described in detail in the Methods section. Depending
on the exposure assessment approach, this resulted in
11 092 (TUA1) and 10 801 (TUA2) participants in
the final analyses. Informed consent was obtained
from all survey participants and study protocols were
approved by the National Center for Health Statistics
(NCHS) Research Ethics Review Board [24].
Serological testing
At the time of examination participants provided
blood via venepuncture. The samples were processed
by the Division of Viral Hepatitis, CDC using a com-
mercial assay (Vitros, Ortho-Clinical Diagnostics,
USA) and determined total antibody (IgG and IgM)
to the HAV (total anti-HAV). Results are obtained
as a normalized signal, relative to a lot-specific cali-
bration cut-off value [signal/cut-off (s/c)]. The total
anti-HAV test relies on a photoluminescent reaction
that is present for negative samples. Subsequently
ratios <1 are considered a positive result. NHANES
evaluates the anti-HAV results as antibody positive
(<0·80 s/c), borderline (50·80 and <1·0 s/c), antibody
negative (51·0 and <4·0 s/c) or retest (54·0 s/c) [25].
Thus, being positive for total anti-HAV (seropositive)
indicates the person has been previously infected with
HAV or has been vaccinated against HAV. Being
negative for anti-HAV (seronegative) indicates the per-
son has not been infected with HAV or has not been
vaccinated against HAV. NHANES only reports results
as positive, negative or intermediate as quantitative
results cannot be correlated to an endpoint titre [25].
Self-reported immunization
Participants were asked to recall their hepatitis A
immunization history for all NAHNES cycles and sub-
sequently classified as receiving: 52 doses, <2 doses,
no dose, refused, and ‘don’t know’. Participants that
refused to answer the question were excluded from
the analysis (n= 7).
Urinary arsenic assessment
The analytical method to quantify arsenic metabolites
in urine has been previously described [26] and
consistent across cycles although the sensitivity of
the reporting improved in 2011. Briefly, spot urine
samples were obtained at the time of the physical exam-
ination in arsenic-free containers, shipped on dry
ice, stored at 4–70 °C and analysed within 3 weeks
of sampling at the Environmental Health Sciences
Laboratory using high-performance liquid chroma-
tography coupled to an inductively coupled-plasma
dynamic reaction cell-mass spectrometry [25]. The
limits of detections (LOD) for the 2003–2010 survey
cycles were as follow: arsenate (1·0 µg/l), arsenite
(1·20 µg/l), dimethylarsonic acid (1·70 µg/l), mono-
methylarsonic acid (0·90 µg/l), arsenobetaine (0·40
µg/l), arsenocholine (0·60 µg/l) and TUA (0·74 µg/l).
The limits of detection for the 2011–2012 survey
cycle were slightly different: arsenate (0·87 µg/l),
arsenite (0·48 µg/l), dimethylarsonic acid (1·80 µg/l),
monomethylarsonic acid (0·89 µg/l), arsenobetaine
(1·19 µg/l), arsenocholine (0·28 µg/l) and TUA (1·25
µg/l). The proportion of participants that were below
the LOD for the combined survey cycles was 95·9%
for arsenate, 90·1% for arsenite, 67·6% for mono-
methylarsonic acid, 18·0% for dimethylarsonic acid,
40·86% for arsenobetaine, 97·60% for arsenocholine,
and 1·28% for TUA.
Arsenic and total hepatitis A antibodies 1643
If a metabolite was below the LOD, a value equiva-
lent to the LOD divided by the square root of 2 was
assigned. TUA1 was defined as the sum of arsenate,
arsenite, dimethylarsonic acid, and monomethylar-
sonic acid. Additionally, we defined TUA2 as the
total urinary arsenic minus arsenobetaine and arseno-
choline as a complementary approach to evaluate
total arsenic exposure. For TUA2, 211 participants
had urinary arsenobetaine and arsenocholine levels
greater than TUA, yielding negative levels for
TUA2. This would indicate that these individuals
had recently consumed seafood which is naturally
high in these compounds [27]. Since these organoarse-
nic compounds are considered to be less toxic than in-
organic arsenic and its metabolites, these participants
were excluded from analyses that used TUA2. In sen-
sitivity analyses replacing these 211 values with the
LOD for TUA divided by the square root of 2 did
not affect the observed association (results not
shown). Both approaches used to model total urinary
arsenic (TUA1 and TUA2) concentration should not
be influenced by organoarsenic compounds found in
seafood [28].
Covariates
Previous research has described differences in urinary
arsenic levels by age, sex, race and gender in the US
population [28]. Additionally, the prevalence of
HAV has been shown to differ by age, gender, race
and country of birth [29]. Subsequently, these covari-
ates were extracted from the five NHANES cycles and
further evaluated for adjustment in multivariate mod-
els. Race/ethnicity was reported as non-Hispanic
white, non-Hispanic black, Mexican American,
other Hispanic and other race including multiracial.
Economic status was evaluated by using the family’s
income to poverty ratio. Body mass index (BMI)
was reported in kg/m2. As suggested by the NCHS,
the effect of spot urine dilution was accounted for
by adjusting for creatinine (mg/dl) concentration in
all multivariate models. Survey year was included in
the analysis to control for temporal changes in HAV
serology and arsenic exposure.
Statistical analysis
Sampling weights were calculated for the arsenic sub-
sample of NHANES from 2003 to2012 by rescaling
the survey weights of each cycle by multiplying the ar-
senic subsample weight by 1/5, as recommended by
the analytical guidelines of NHANES [30]. To ac-
count for the complex survey design implemented by
NHANES, all analyses used survey weights, primary
sampling units and strata. However, we also con-
ducted a sensitivity analysis by removing the weights.
Statistical significance was evaluated using a cut-off
value of α4 0·05, and all tests performed were two-
tailed. Standard errors (S.E.s) and 95% confidence
intervals (CIs) were estimated using the Taylor linear-
ization method. All statistical analyses were per-
formed using Stata v. 12.1 (StataCorp LP, USA).
The distribution of TUA1, TUA2 and creatinine
were right-skewed and subsequently natural log-
transformed. The geometric mean and the S.E. for
total arsenic (TUA1 and TUA2) was estimated across
categories of sex, race, family income/poverty ratio,
BMI, age, country of birth, and seroprevalence of
total anti-HAV and evaluated using linear regression
models and a Wald test adjusted for creatinine con-
centration to account for urine dilution. Bivariate
associations between all covariates and total-anti
HAV seroprevalence were evaluated and adjusted
for in multivariate models if differences were
observed. Multivariate logistic regression models
were used to estimate the odds of being seropositive
for total anti-HAV adjusting for log-transformed cre-
atinine (continuous), age (continuous), sex, race, fam-
ily income/poverty ratio (continuous), country of
birth, BMI (continuous) and survey year. To evaluate
effect modification the multiplicative interaction be-
tween log-transformed TUA1 and TUA2, and self-
reported vaccination status were tested using a Wald
test adjusting for all covariates. Odds ratios (ORs)
and 95% CIs were estimated for each level of self-
reported hepatitis A immunization from adjusted
models that included the multiplicative interaction be-
tween exposure and immunization history to estimate
the association between total arsenic exposure and
hepatitis A seroprevalence.
RESULTS
The geometric means of TUA for selected population
characteristics are presented in Table 1. Overall, TUA
was slightly higher for females, in individuals report-
ing to be multiracial or of other race followed by
Mexican Americans, and in individuals living in
households above the poverty level for TUA2 but
not for TUA1. BMI was also associated with TUA
and with age. Individuals born in the United States
had significantly lower TUA compared to individuals
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born elsewhere. Urinary arsenic was higher in sero-
positive anti-HAV participants compared to seronega-
tive individuals. No differences in TUA were observed
by self-reported immunization status to HAV.
The total anti-HAV seroprevalence (e.g. seroposi-
tive) for selected population characteristics are pre-
sented in Table 2. Across all 10 years, the overall
seropositive prevalence was estimated to be 35·1%
(95% CI 33·3–36·9). Seropositive prevalence of total
anti-HAV was highest in Mexican Americans (75%),
participants living below the poverty level (45%), chil-
dren aged 6–11 years (44%), participants in the lowest
urinary creatinine tertile (38%), individuals not born
in the United States (77%) and in individuals that self-
reported receiving 52 doses of hepatitis A vaccine
(52%). Total anti-HAV seropositive prevalence was
elevated for participants in the highest quartile of ar-
senic exposure compared to the third, second and
first quartiles for TUA1 (43%) or TUA2 (42%). In
our restricted sample for TUA1, a total of 26·51%
individuals reported receiving 52 doses of hepatitis
A vaccine, 2·46% reported receiving <2 doses,
59·53% participants reported receiving no dose and
11·49% participants reported not knowing whether
Table 1. Weighted geometric mean (GM) and standard error (S.E.) of total urinary arsenic levels (μg/l) adjusted for
log-transformed creatinine, NHANES 2003–2012
TUA1* TUA2†
Population characteristic (N= 11092) GM (S.E.)‡ (N = 10 801) GM (S.E.)‡
Overall 6·34 (1·01) 5·06 (1·02)
Sex P= 0·026 P= 0·074
Male 5517 6·40 (1·02) 5408 5·19 (1·02)
Female 5575 6·58 (1·01) 5393 5·40 (1·03)
Race P< 0·001 P< 0·001
Mexican American 2267 6·91 (1·02) 2222 5·93 (1·03)
Other Hispanic 821 8·07 (1·02) 799 7·19 (1·04)
Non-Hispanic white 4593 6·18 (1·02) 4443 4·89 (1·03)
Non-Hispanic black 2637 6·08 (1·02) 2588 4·84 (1·04)
Other race/multiracial 774 9·79 (1·04) 749 10·38 (1·06)
Family income/poverty ratio P= 0·2885 P= 0·010
Below poverty level41 2771 6·38 (1·02) 2703 4·95 (1·03)
Above poverty level >1 8321 6·50 (1·01) 8098 5·37 (1·03)
Body mass index (kg/m2) P< 0·001 P< 0·001
Underweight 264 6·44 (1·04) 257 5·53 (1·08)
Normal weight 4342 6·73 (1·02) 4218 5·59 (1·03)
Overweight 3132 6·58 (1·02) 3053 5·38 (1·03)
Obese 3354 6·12 (1·01) 3273 4·89 (1·03)
Age (years) P< 0·001 P< 0·001
6–11 1420 7·06 (1·02) 1377 6·00 (1·03)
12–19 2226 5·68 (1·02) 2177 4·00 (1·03)
520 7446 6·56 (1·01) 7247 5·46 (1·03)
Country of birth P< 0·001 P< 0·001
United States 8863 6·16 (1·01) 8619 4·87 (1·03)
Elsewhere 2229 8·75 (1·02) 2182 8·65 (1·04)
Hepatitis A immunization P= 0·104 P= 0·051
52 doses 2941 6·68 (1·02) 2854 5·65 (1·03)
<2 doses 273 6·52 (1·03) 268 5·46 (1·08)
0 dose 6603 6·41 (1·01) 6438 5·20 (1·03)
Don’t know 1275 6·52 (1·02) 1241 5·18 (1·04)
Hepatitis A (anti-HAV) P< 0·001 P< 0·001
Seropositive 5064 7·12 (1·02) 4934 6·19 (1·03)
Seronegative 6028 6·17 (1·01) 5867 4·88 (1·03)
* TUA1 =AsIII + AsV +MMA+DMA.
†TUA2 = total urinary As – arsenocholine – arsenobetaine.
‡Models adjusted for log-transformed creatinine.
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they received a dose of the HAV vaccine. A similar
self-reported HAV immunization distribution was
observed for TUA2.
The ORs for the association between TUA and
total anti-HAV seropositive prevalence were estimated
for each self-reported category of hepatitis A
Table 2. Hepatitis A seroprevalence (total anti-HAV) by demographic characteristics: NHANES: 2003–2012
Hepatitis A seroprevalence (total anti-HAV)
TUA1* TUA2†
Population characteristics (N= 11 092) Seropositive (95% CI) (N = 10 801) Seropositive (95% CI)
Overall prevalence 5064 35·1% (33·3–36·9) 4934 34·9% (33·1–36·7)
Sex P = 0·926 P= 0·936
Male 5517 35·0% (32·7–37·4) 5408 34·9 (32·5–37·3)
Female 5575 35·1% (33·1–37·1) 5393 34·9 (32·9–36·9)
Race P < 0·001 P< 0·001
Mexican American 2267 75·5% (72·9–78·1) 2222 75·4% (72·8–78·1)
Other Hispanic 821 63·2% (58·5–68·0) 799 63·1% (58·4–67·8)
Non-Hispanic white 4593 25·5% (23·9–27·2) 4443 25·2% (23·5–26·9)
Non-Hispanic black 2637 36·9% (34·3–39·6) 2588 36·9% (34·4–39·6)
Other race/multiracial 774 57·8% (52·5–62·9) 749 57·8% (52·6–62·9)
Family income/poverty ratio P < 0·001 P< 0·001
Below poverty level 41 2771 45·4% (31·9–34·9) 2703 45·3% (41·8–48·9)
Above poverty level >1 8321 33·1% (31·4–34·9) 8098 32·9% (31·2–34·7)
Body mass index (kg/m2) P = 0·138 P= 0·168
Underweight 264 31·6% (24·2–39·1) 257 32·6% (24·9–40·3)
Normal weight 4342 35·8% (33·2–38·4) 4218 35·8% (33·2–38·5)
Overweight 3132 35·9% (33·6–38·2) 3053 35·6% (33·4–37·8)
Obese 3354 33·6% (31·3–35·9) 3273 33·3% (30·9–35·7)
Age (years) P < 0·001 P< 0·001
6–11 1420 44·2% (39·7–49·3) 1377 44·8% (39·6–49·9)
12–19 2226 36·4% (32·3–40·4) 2177 35·9% (31·6–40·3)
520 7446 33·9% (33·4–37·4) 7247 33·8% (32·0–35·6)
Creatinine (mg/dl) (tertiles) P < 0·001 P< 0·001
(6–75) 3367 37·9% (35·5–40·3) 3175 37·8% (35·3–40·2)
(76–145) 3850 36·7% (34·2–39·1) 3804 36·5% (34·1–38·9)
(146–800) 3875 30·7% (28·3–33·1) 3822 30·6% (28·2–33·0)
Country of birth P < 0·001 P< 0·001
United States 8863 27·9% (26·3–29·6) 8619 27·7% (26·1–29·4)
Elsewhere 2229 76·9% (73·7–80·0) 2182 76·6% (73·3–79·9)
TUA1 (μg/l) (quartiles) P < 0·001
2·69–4·14 2470 32·9% (30·2–35·6) – –
4·15–5·89 2755 32·4% (29·3–34·8) – –
5·90–8·54 2848 31·9% (29·4–34·5) – –
8·55–628 3019 43·1% (40·1–46·0) – –
TUA2 (μg/l) (quartiles) P< 0·001
0–2·72 – – 2460 31·6% (29·1–34·1)
2·73–5·3 – – 2661 33·6% (30·9–36·3)
5·31–9·88 – – 2824 32·9% (29·7–36·0)
9·89–718·9 – – 2856 41·8% (38·9–44·8)
Hepatitis A immunization P < 0·001 P< 0·001
52 doses 2941 51·9% (48·8–55·0) 2854 52·0% (48·9–55·2)
<2 doses 273 41·6% (33·3–49·8) 268 41·9% (33·6–50·4)
0 dose 6603 29·1% (27·3–30·9) 6438 28·8% (26·9–30·6)
Don’t know 1275 35·0% (31·1–38·9) 1241 35·3% (31·5–39·1)
CI, Confidence interval.
* TUA1 =AsIII + AsV +MMA+DMA.
†TUA2 = total urinary As – arsenocholine – arsenobetaine.
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immunization from adjusted logistic regression
models that included the multiplicative interaction be-
tween log-transformed urinary arsenic (TUA1 and
TUA2) and self-reported hepatitis A immunization
(Table 3). In multivariate models the multiplicative
interaction between continuous log-transformed
TUA1 and self-reported hepatitis A vaccination as
categorical outcome (52 doses, <2 doses, no dose,
‘don’t know’) was statistically significant (Wald P =
0·032) as well as with TUA2 (Wald P= 0·010) after
adjusting for log-transformed creatinine, age, sex,
race, BMI, family income/poverty ratio, country of
birth and survey year. In adjusted analysis, partici-
pants that self-reported receiving the complete two
doses of hepatitis A vaccine had 42% greater odds of
testing positive for total anti-HAV for every unit in-
crease in log-transformed TUA1 levels (OR 1·42,
95% CI 1·11–1·81). Similarly, the adjusted odds of
testing positive for total anti-HAV (e.g. seropositive)
increased by 17% for every unit increase in log-
transformed TUA2 (OR 1·17, 95% CI 1·04–1·31).
The odds of testing positive for total anti-HAV
increased by 75% for every unit increase in log-
transformed TUA1 levels in participants reporting
not knowing whether they have received a hepatitis
A vaccine dose (OR 1·75, 95% CI 1·22–2·52). A mar-
ginal increase of 20% was also observed for this group
in the adjusted odds of being positive for total
anti-HAV for every unit increase in log-transformed
TUA2 (OR 1·20, 95% CI 0·97–1·48). No association
was observed for participants that self-reported receiv-
ing <2 doses of hepatitis A vaccine for TUA1 (OR
1·46, 95% CI 0·83–2·59) or TUA2 (OR 1·26, 95%
CI 0·95–1·67) or for individuals that reported
receiving no dose of the vaccine for TUA1 (OR
1·12, 95% CI 0·98–1·30) or TUA2 (OR 1·07, 95%
CI 0·99–1·16). Results were consistent when models
were stratified by self-reported vaccination status or
analysed without the sampling design and weights
(results not shown). The observed relationship
remained consistent when total arsenic was modelled
by quartiles of exposure of TUA1 (Fig. 1) or TUA2
(Fig. 2). Age did not modify the observed association.
DISCUSSION
This cross-sectional study observed that higher arsenic
exposure levels were associated with a greater prob-
ability of total anti-HAV seropositive prevalence in
the US population aged 56 years.
This dose-dependent association was consistently
positive in all self-reported immunization strata but
only reaches statistical significance in individuals
that reported receiving 52 doses of HAV immuniza-
tion and for participants that did not know whether
they had received HAV immunization. Given the
cross-sectional nature of this study and reliance on
total anti-HAV as the outcome, we cannot ascertain
whether arsenic exposure is related to increased risk
of hepatitis A infection or if toxic exposure modulates
the immunological response to vaccination since a
positive total anti-HAV test is not able to distinguish
between a present, previous infection, or vaccine-
induced immunity [31]. This is because hepatitis A
IgM indicates a current underlying infection but hepa-
titis A IgG indicates immunity or recovery from a pre-
vious natural infection [32]. Furthermore, it is
unknown if anti-HAV levels diminish over time.
However, total anti-HAV is commonly used in epi-
demiological studies to measure the overall prevalence
of previous infections [8]. The active production of the
IgG antibody by vaccination can be 10- to 100-fold
Table 3. Adjusted odds ratios* for the association of total urinary arsenic levels and total anti-HAV seropositive
prevalence by self-reported immunization status
52 doses <2 doses 0 dose Don’t know
Exposure assessment aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI)
Ln TUA1† 1·42 (1·11–1·81) 1·46 (0·83–2·59) 1·12 (0·98–1·30) 1·75 (1·22–2·52)
Ln TUA2‡ 1·17 (1·04–1·31) 1·26 (0·95–1·67) 1·07 (0·99–1·16) 1·20 (0·97–1·48)
aOR, Adjusted odds ratio; CI, confidence interval.
* Odds ratios from a logistic regression model that included the interaction between arsenic exposure (TUA1 or TUA2) and
hepatitis A vaccine adjusted for log-transformed creatinine, age, sex, race, family income/poverty ratio, country of birth, body
mass index and survey year.
†TUA1 =AsIII + AsV +MMA+DMA.
‡TUA2 = total urinary As – arsenocholine – arsenobetaine (excluding negatives levels due to arsenocholine + arsenobetaine
> total As).
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lower compared to IgG antibody levels produced by
natural infections and in many instances present
below the detection limit for many commercial assays
including the assay used by NHANES [8]. This is also
highlighted in our data that shows that only 52% of
individuals that self-reported receiving 52 doses of
HAV vaccine tested seropositive for total anti-HAV.
It is possible, however, that this could also originate
from recall bias from participants as the sensitivity
of self-reported HAV immunization has been
estimated to be 63% compared to electronic medical
records [33]. While we cannot rule out misclassifica-
tion it is likely to be non-differential in relationship
to urinary arsenic concentrations which is unlikely
to be known by an individual. Thus, a possible explan-
ation of our findings is that arsenic exposure may be
associated with a lower protective immunity provided
by the HAV immunization, which may subsequently
result in HAV infection yielding a stronger antibody
response.
Fig. 1. Adjusted odds ratios* for the association between total urinary arsenic (TUA1) in quartiles and total anti-HAV
seropositive prevalence by self-reported HAV immunization: (a) received 52 doses, (b) received <2 doses, (c) 0 dose and
(d) ‘don’t know’. [* Odds ratios from a logistic regression model that included the interaction between arsenic exposure by
quartiles (TUA1) and hepatitis A immunization adjusted for log-transformed creatinine, age, sex, race, family income/
poverty ratio, country of birth, body mass index and survey year.]
Fig. 2. Adjusted odds ratios* for the association between total urinary arsenic (TUA2) in quartiles and total anti-HAV
seropositive prevalence by self-reported HAV immunization: (a) received 52 doses, (b) received <2 doses, (c) 0 dose and
(d) ‘don’t know’. [* Odds ratios from a logistic regression model that included the interaction between arsenic exposure by
quartiles (TUA2) and hepatitis A immunization adjusted for log-transformed creatinine, age, sex, race, family income/
poverty ratio, country of birth, body mass index and survey year.]
1648 A. Cardenas and others
This interpretation contradicted our initial hypoth-
esis that HAV vaccination would be protective
of the immunotoxic effect from arsenic exposure.
Additionally, the absence of an association for indivi-
duals receiving no dose of the vaccine or <2 doses
could be attributed to the lack of protection of not re-
ceiving the adequate immunization so differential ex-
posure to arsenic, either high or low, would not
affect the susceptibility to infection or immune re-
sponse of these subgroups. The observed significant
association for protected individuals (self-reported re-
ceiving two doses) or the mixture of protected/unpro-
tected individuals (self-reporting not knowing whether
they received any dose) could be influenced by arsenic
exposure levels by either: (a) decreasing protecting im-
munity of the vaccine or (b) altering antibody re-
sponse to the hepatitis A vaccine. Arsenic could
contribute to the dysregulation of IgG or IgM antibody
production in vaccinated participants yielding higher
detectable levels of total anti-HAV. Additional studies
are needed to test the hypothesis that arsenic reduces
vaccine-induced immunity conferred by HAV vaccin-
ation or whether it actually increases susceptibility to
hepatitis A infection. A recent epidemiological investi-
gation demonstrated that elevated urinary arsenic levels
during pregnancy increase the incidence of hepatitis
E virus seroconversion, suggesting that environmental
arsenic exposure enhances susceptibility to hepatitis
E viral infection [22]. Further studies are therefore war-
ranted to determine if arsenic exposure can influence
susceptibility to hepatitis A.
There is considerable evidence that arsenic affects
the immune system. Experimental studies in zebrafish
have demonstrated that exposure of arsenic at envir-
onmentally relevant concentrations compromised the
overall innate and adaptive immune system [34, 35].
In vivo studies have also shown that arsenic exposure
increases the percentage and total levels of CD8+ T
cells, and decreases cytokine production [36].
Alterations in gene expression related to the immune
response, including genes involved in T-cell receptor
signalling have also been observed with increased ex-
posure to inorganic arsenic [37, 38]. T cells play a
key role in the immune response to infections and
vaccine-induced immunity that could modulate
arsenic’s induced immunotoxicity [39]. Recent evi-
dence from birth cohorts have demonstrated that in
utero exposure to arsenic altered the CD4 + /CD8 +
T-cell ratios and also slightly decreased the proportion
of B cells in newborns [40, 41]. The key role of T cells
in stimulating B cells for the production of antibodies
makes T-cell regulation a likely target for the observed
association.
This study has several strengths including the use of
a large recently collected representative sample of the
US population across a time period of 9 years. Arsenic
exposure levels represent exposure at environmentally
relevant concentrations and our complementary ap-
proach of using two different methods for assessing
exposure yielded consistent results. The use of several
biomarkers of arsenic exposure and the meticulous
quality control procedures for the analysis and collec-
tion of specimens implemented by NHANES are also
important strengths. However, our study also has sev-
eral limitations. Primarily, total anti-HAV seroposi-
tivity is unable to differentiate between a present or
previous infection and vaccine-induced immunity.
Furthermore, the assay used by NHANES is qualita-
tive and cannot be correlated to a titre endpoint. The
data were collected cross-sectionally and therefore we
cannot evaluate temporality of this association be-
tween arsenic and anti-HAV response. While we
were able to adjust for major risk factors of HAV in-
fection identified in the literature, the possibility of re-
sidual confounding cannot be ruled out. Moreover,
despite the strengths of using a biomarker of internal
dose to ascertain arsenic exposure, urinary arsenic
was measured only at one point in time and we ac-
knowledge that exposure may fluctuate over time.
The possibility for reverse causation of viral hepatitis
modifying the metabolism and excretion of urinary ar-
senic cannot be ruled out and should be considered in
future studies. NHANES does not sample institutio-
nalized or homeless individuals and it is expected
that the prevalence of HAV would be much higher
in these individuals.
CONCLUSION
Overall, elevated arsenic exposure was positively asso-
ciated with the seroprevalence of total anti-HAV in
participants receiving 52 doses of HAV vaccine and
for individuals unable to recall their immunization
history after adjusting for major risk factors and po-
tential confounders. The elevated prevalence of sero-
logical markers suggests that arsenic exposure may
alter the immune response to HAV and this relation-
ship was modified by self-reported immunization sta-
tus. This study generates hypotheses for further
study that are designed to understand whether arsenic
exposure alters the immune response to hepatitis A or
alters the response to vaccine-induced immunity.
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